Filing Details
- Accession Number:
- 0001209191-18-056046
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-10-24 16:16:59
- Reporting Period:
- 2018-10-22
- Accepted Time:
- 2018-10-24 16:16:59
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1169245 | Phasebio Pharmaceuticals Inc | PHAS | Pharmaceutical Preparations (2834) | 1231 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 901832 | Plc Astrazeneca | 1 Francis Crick Avenue Cambridge X0 CB2 0AA | No | No | Yes | No | |
| 1657583 | Zeneca, Inc. | C/O Astrazeneca Plc 1 Francis Crick Avenue Cambridge X0 CB2 0AA | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-10-22 | 2,404,554 | $0.00 | 2,404,554 | No | 4 | C | Indirect | By Zeneca, Inc. |
| Common Stock | Acquisiton | 2018-10-22 | 600,000 | $5.00 | 3,004,554 | No | 4 | P | Indirect | By Zeneca, Inc. |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | By Zeneca, Inc. |
| No | 4 | P | Indirect | By Zeneca, Inc. |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Series C-1 Preferred Stock | Warrants to Purchase Series C-1 Preferred Stock | Disposition | 2018-10-22 | 113,891 | $0.00 | 113,891 | $0.12 |
| Common Stock | Series C-1 Preferred Stock | Acquisiton | 2018-10-22 | 113,891 | $0.12 | 113,891 | $0.00 |
| Common Stock | Series C-1 Preferred Stock | Disposition | 2018-10-22 | 2,734 | $5.00 | 2,734 | $0.00 |
| Common Stock | Series C-1 Preferred Stock | Disposition | 2018-10-22 | 1,664,217 | $0.00 | 1,664,217 | $0.00 |
| Common Stock | Series D Preferred Stock | Disposition | 2018-10-22 | 740,337 | $0.00 | 740,337 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | X | Indirect | ||
| 1,666,951 | No | 4 | X | Indirect | ||
| 1,664,217 | No | 4 | S | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.
- Zeneca Inc. is a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC may be deemed to beneficially own the securities held by Zeneca Inc., but disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, if any.
- Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.
- The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.
Billionaire Hedge Funds
